On August 27, Madrigal Pharmaceuticals rose 5.08% in regular trading, trading at $537.92/share, with Turnover of $124 million.

Within the Biotechnology sector where Madrigal Pharmaceuticals belongs, the stock notably outperformed peers. Among individual stocks, Moderna down 7.67%, Revolution Medicines down 0.07%, Amgen down 0.16%, AbbVie down 1.61%, Gilead Sciences down 0.03%.

Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH). Its core product Rezdiffra is a once-daily oral liver-directed thyroid hormone receptor beta agonist. The company reported Q2 Rezdiffra net sales of $364.3 million, representing 71% year-over-year growth, with more than 49,000 patients on therapy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)